# China National Biotec Group Company trials: 37 (2026)

ClinicalTrials.gov lists 37 trials with China National Biotec Group Company Limited as lead sponsor, 2 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by China National Biotec Group Company Limited: 37 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/china-national-biotec-group-company-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 29, 2026 | NCT07377175 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. | China National Biotec Group Company Limited | Phase 1 | Recruiting | Smallpox, Cowpox, Monkeypox, Poxvirus Infection | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377175) |
| January 14, 2026 | NCT07338851 | the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines | China National Biotec Group Company Limited | Observational | Not yet recruiting | Polio, Measles, Rubella, Mumps, Hepatitis A | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07338851) |
| May 3, 2023 | NCT05839301 | A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age | China National Biotec Group Company Limited | Phase 3 | Unknown | Varicella | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05839301) |
| January 3, 2023 | NCT05669625 | A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine | China National Biotec Group Company Limited | Phase 3 | Unknown | Varicella | 12,440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05669625) |
| July 29, 2022 | NCT05480436 | Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population | China National Biotec Group Company Limited | Phase 4 | Unknown | Hemolysis, COVID-19 | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05480436) |
| July 12, 2022 | NCT05453487 | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19, Rabies | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05453487) |
| May 19, 2022 | NCT05382871 | Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above | China National Biotec Group Company Limited | Phase 3 | Unknown | COVID-19 | 1,804 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05382871) |
| May 16, 2022 | NCT05374954 | Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18... | China National Biotec Group Company Limited | Phase 3 | Unknown | COVID-19 | 4,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05374954) |
| May 9, 2022 | NCT05365724 | A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age... | China National Biotec Group Company Limited | Phase 1/2 | Unknown | COVID-19 | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05365724) |
| November 3, 2021 | NCT05105295 | Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19, HIV Infections | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05105295) |
| November 3, 2021 | NCT05104437 | Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension... | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19 Pneumonia | 1,440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05104437) |
| November 3, 2021 | NCT05104333 | Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With... | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19 Pneumonia | 1,440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05104333) |
| November 2, 2021 | NCT05104216 | Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19, Chronic Bronchitis, COPD | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05104216) |
| October 25, 2021 | NCT05091619 | A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed | China National Biotec Group Company Limited | Phase 3 | Active not recruiting | Whooping Cough, Diphtheria, Tetanus | 2,898 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05091619) |
| October 15, 2021 | NCT05079152 | Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 | China National Biotec Group Company Limited | Phase 4 | Unknown | Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia | 1,404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05079152) |
| October 12, 2021 | NCT05075083 | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19, Chronic Bronchitis, COPD | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075083) |
| October 12, 2021 | NCT05075070 | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19, HIV Infections | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075070) |
| October 12, 2021 | NCT05075057 | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19, Chronic Bronchitis, Copd | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075057) |
| October 12, 2021 | NCT05075044 | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected | China National Biotec Group Company Limited | Phase 4 | Unknown | HIV Infections, COVID-19 | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075044) |
| October 4, 2021 | NCT05065892 | Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes | China National Biotec Group Company Limited | Phase 4 | Unknown | COVID-19 Pneumonia | 1,440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05065892) |
| October 4, 2021 | NCT05065879 | Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes | China National Biotec Group Company Limited | Phase 4 | Completed | COVID-19 Pneumonia | 1,440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05065879) |
| June 8, 2021 | NCT04917523 | Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above | China National Biotec Group Company Limited | Phase 3 | Completed | COVID-19 Pneumonia, COVID-19 | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04917523) |
| April 28, 2021 | NCT04863638 | A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated | China National Biotec Group Company Limited | Phase 4 | Unknown | Covid19 | 4,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04863638) |
| March 10, 2021 | NCT04790851 | Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 | China National Biotec Group Company Limited | Phase 4 | Completed | Influenza, Human, Pneumonia, Pneumococcal, Covid19 | 1,133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04790851) |
| January 8, 2021 | NCT04701788 | A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly | China National Biotec Group Company Limited | Phase 4 | Completed | Vaccination | 331 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04701788) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 3 | 7 |
| Phase 4 | 27 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 23 |
| Completed | 11 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 15 |
| Influenza, Human | 4 |
| Pneumonia, Pneumococcal | 3 |
| Bronchitis, Chronic | 3 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| HIV Infections | 3 |
| Chickenpox | 2 |
| Hepatitis A | 2 |
| Coronavirus Infections | 2 |
| Enterovirus Infections | 1 |
| Poliomyelitis | 1 |
| Measles | 1 |
| Rubella | 1 |
| Mumps | 1 |
| Rabies | 1 |
| Smallpox | 1 |
| Cowpox | 1 |
| Mpox, Monkeypox | 1 |
| Poxviridae Infections | 1 |
| Whooping Cough | 1 |
| Diphtheria | 1 |
| Tetanus | 1 |
| Hemolysis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
- [Acoustical consultants in the United States](https://specstream.ai/data/businesses/acoustical-consultants/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [Seafood restaurants in the United States](https://specstream.ai/data/businesses/seafood-restaurants/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
